Developing Countries: Coronavirus

(asked on 13th January 2022) - View Source

Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what progress her Department has made in promoting joint ventures between covid-19 vaccine manufacturers in the UK and local companies in low and middle-income income countries.


Answered by
Amanda Milling Portrait
Amanda Milling
Government Whip, Lord Commissioner of HM Treasury
This question was answered on 18th January 2022

The UK backs the Oxford-AstraZeneca model of voluntary licensing to expand the production of affordable vaccines. With UK Government support, a global licencing deal helped transfer AZ's technology to other manufacturers and establish 20 supply chains across the world, including the Serum Institute of India. Around 2.5 billion Oxford-AstraZeneca doses have been delivered at cost to more than 170 countries. Almost two-thirds of these have gone to low and lower-middle-income countries, including more than 30 million doses donated by the UK through COVAX or bilaterally.

The UK has provided technical support to develop business cases for Biovac to manufacture vaccines in South Africa, Institut Pasteur in Senegal and to the Moroccan government. This technical support helped catalyse investment that will see COVID-19 vaccines produced on the African continent in 2022. We are also engaging with the new Partnership for African Vaccine Manufacturing to support development of its roadmap for African vaccine manufacturing.

Reticulating Splines